OpGen Inc (OPGN) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

OpGen (OPGN) - corporate logo

OpGen, Inc. (OPGN) automates pathogen detection using robotic systems that eliminate human error. The available price action vector based on the EV/EBITDA metric is . OpGen, Inc. (OPGN) relies on the high value of Acuitas tests in clinics where demand remains stable. Production is scaling through partnerships with CDMO contractors, while risks are minimized via strict quality control and long-term agreements.

OpGen Inc - OPGN Company Value to Operating Income Before Depreciation Ratio (period 07/04/2022 - 11/11/2026)

Summary analytical data breakdowns for opgen.com (OPGN)

- current price and projected stock value:
Stock Price OpGen Corp|OPGN - Analyst Median Target
- market capitalization details:
Market Value OpGen Corporation|OPGN - Business Value
- book value of equity indicators:
Book Value per Share OpGen|OPGN - Net Asset Value|Market Capitalization to Book Value Ratio opgen.com|OPGN - Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital OpGen, Inc.|OPGN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio OpGen|OPGN - Company Cumulative Indebtedness|Debts to Book Capitalization OpGen Corporation|OPGN - Long-Term Debt Volume|Company Short-Term Debt OpGen|Quick Liquidity opgen.com
- financial results and valuation multiples details:
OPGN - Company Profit|Expected Profit OpGen, Inc.|OPGN - Business Payback Period|Future Price to Earnings OpGen, Inc.|OPGN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OpGen Corporation|OPGN - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) OpGen|OPGN - Net earnings per share for the trailing year|Quarterly EPS earnings growth opgen.com|OPGN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year OpGen, Inc.
General company analysis:OpGen Corp OPGN
Product sample of OpGen Inc

The multiple compares the total enterprise value, including net debt, to operating profit before depreciation and amortization. This ratio determines the issuer's maturity phase and the stability of its model through the discounting of future cash flows. The weak pricing power of OpGen, Inc. (OPGN) in the molecular diagnostics segment limits EBITDA growth, which is reflected in the EV/EBITDA value over time as a signal of capital impairment risk.

Analysis of competing companies

EV/EBITDA Multiple SMMT (Summit Therapeutics Inc)|Total Company Value to Operating Income Before Depreciation Ratio Moderna Therapeutics (MRNA)|PCVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TARS (tarsusrx.com) - Enterprise Value to Operating Income Before Depreciation|CRMD: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio MCRB (Seres Therapeutics Inc.)|SPRO (Spero) - EV/EBITDA Multiple|Company Value to EBITDA Scynexis SCYX|EV/EBITDA Multiple ANTX|Enterprise Value to EBITDA Ratio polypid.com PYPD|LakeShore Biopharma - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ITRM (Iterum Therapeutics PLC)|BiomX Ltd - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Soligenix, Inc. SNGX|60degreespharma.com (SXTP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA oragenics.com (OGEN)